Τwo additional clinical trials enrolling SCD patients, performed by Graphite Bio, Inc [NCT04819841; GPH101-001; CEDAR] and Editas Medicine, Inc [NCT04853576; EM-SCD-301-001], target ex vivo BCL11A disruption in patients derived CD34+ cells via CRISPR-Cas9 system [173] (Table S2). This evidence concerns the gene CD34 and Schnyder corneal dystrophy.